Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas

NCT01442662 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01442662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01442662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
May 28, 2019
Enrollment
106 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma